Pharmacia and Upjohn
22
0
0
19
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
13.6%
3 terminated/withdrawn out of 22 trials
86.4%
-0.1% vs industry average
18%
4 trials in Phase 3/4
16%
3 of 19 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
Role: collaborator
Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Role: collaborator
Irinotecan in Treating Patients With Esophageal or Stomach Cancer
Role: collaborator
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
Role: collaborator
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
Role: collaborator
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
Role: collaborator
Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction
Role: collaborator
Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Role: collaborator
Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
Role: collaborator
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer
Role: collaborator
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Role: collaborator
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
Role: lead
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
Role: lead
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
Role: lead
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
Role: lead
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
Role: lead
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
Role: lead
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
Role: lead
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
Role: lead
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
Role: lead